| Code | CSB-RA006163MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Tremelimumab, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a critical immune checkpoint receptor expressed on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. By delivering inhibitory signals, CTLA4 maintains immune homeostasis and prevents excessive T-cell responses. Dysregulation of CTLA4-mediated immune suppression is implicated in various cancers, where tumor cells exploit this checkpoint to evade immune surveillance, making it a significant target in immuno-oncology research.
Tremelimumab is a fully humanized IgG2 monoclonal antibody that blocks CTLA4, thereby enhancing anti-tumor immune responses through T-cell activation. This biosimilar antibody serves as a valuable research tool for investigating CTLA4 biology, immune checkpoint mechanisms, and T-cell regulation in various disease models. It enables studies exploring combination immunotherapy strategies, tumor microenvironment dynamics, and immune evasion mechanisms in cancer research.
There are currently no reviews for this product.